Renal Replacement Therapy in Severe Burns: A Multicenter Observational Study

Kevin K. Chung, MD,*† Elsa C. Coates, RN,‡ William L. Hickerson, MD,¶ Angela L. Arnold-Ross, RN,‖ Daniel M. Caruso, MD,§§ Marlene Albrecht, RN,¶¶ Brett D. Arnoldo, MD,¶¶ Christina Howard,¶¶ Laura S. Johnson, MD,‡‡ Melissa M. McLawhorn, RN,§§ Bruce Friedman, MD,†† Amy M. Sprague, MD,†† Michael J. Mosier, MD,‡ David J. Smith Jr., MD,¶¶ Rachel A. Karlnoski, PhD,¶¶ James K. Aden, PhD,¶ Elizabeth A. Mann-Salinas, PhD† and Steven E. Wolf, MD,*

*Brooke Army Medical Center, Fort Sam Houston, Texas; †Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, Maryland; ‡United States Army Institute of Surgical Research, Fort Sam Houston, Texas; ¶University of Tennessee Firefighters’ Regional Burn Center, Memphis, Tennessee; ¶¶Arizona Burn Center Maricopa Integrated Health Systems, Phoenix, Arizona; §University of Texas Southwestern Medical Center, Dallas, Texas; ††MedStar Washington Hospital Center, Washington DC; ‡‡Doctors Hospital Joseph M. Still Burn Center, Augusta, Georgia; ||Loyola University Medical Center, Maywood, Illinois; |||University of South Florida Tampa General Hospital, Tampa, Florida and ||||Deceased

Reprints address: Kevin K. Chung, MD, Brooke Army Medical Center, 3551 Roger Brooke Drive, JBSA-Fort Sam Houston, TX 78234. Email: kevin.k.chung.mil@mail.mil

Author’s Contributions: All authors made substantial contributions to conception and design, and acquisition of data. The following authors made substantial contributions to analysis and interpretation of data: K.K.C., W.L.H., D.M.C., B.D.A., L.S.J., B.F., A.M.S., M.J.M., D.J.S., J.K.A., E.A.M., and S.E.W. The following authors were involved in drafting the manuscript: K.K.C. and J.K.A. The following authors were involved in revising the manuscript critically for important intellectual content: K.K.C., E.C.C., W.L.H., M.J.M., B.F., E.A.M., and S.E.W. All authors gave final approval of the final manuscript to be published. Presented as an oral presentation at the 48th American Burn Association Annual Meeting in Boston, Massachusetts on March 24, 2017. The opinions or assertions contained herein are the private views of the authors and are not to be construed as official or as reflecting the views of the Department of the Army, Air Force, or the Department of Defense.

Address correspondence to Kevin K. Chung, MD, Brooke Army Medical Center, 3551 Roger Brooke Drive, JBSA-Fort Sam Houston, TX 78234. Email: kevin.k.chung.mil@mail.mil

© The Author(s) 2018. Published by Oxford University Press on behalf of the American Burn Association. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
doi:10.1093/jbcr/irv036

Acute kidney injury (AKI) after severe burns is historically associated with a high mortality. Over the past two decades, various modes of renal replacement therapy (RRT) have been used in this population. The purpose of this multicenter study was to evaluate demographic, treatment, and outcomes data among severe burn patients treated with RRT collectively at various burn centers around the United States. After institutional review board approval, a multicenter observational study was conducted. All adult patients aged 18 or older, admitted with severe burns who were placed on RRT for acute indications but not randomized into a concurrently enrolling interventional trial, were included. Across eight participating burn centers, 171 subjects were enrolled during a 4-year period. Complete data were available in 170 subjects with a mean age of $51 \pm 17$ percent total body surface area burn of $38 \pm 26\%$ and injury severity score of $27 \pm 21$. Eighty percent of subjects were male and 34% were diagnosed with smoke inhalation injury. The preferred mode of therapy was continuous venovenous hemofiltration at a mean delivered dose of $37 \pm 19$ (ml/kg/hour) and a treatment duration of $13 \pm 24$ days. Overall, in hospital, mortality was 50%. Among survivors, 21% required RRT on discharge from the hospital while 9% continued to require RRT 6 months after discharge. This is the first multicenter cohort of burn patients who underwent RRT reported to date. Overall mortality is comparable to other critically ill populations who undergo RRT. Most patients who survive to discharge eventually recover renal function. (J Burn Care Res 2018;39:1017–1021)
MATERIALS AND METHODS

After multilevel institutional review board approval, a multicenter observational study was conducted; concurrent with the American Burn Association’s Randomized controlled Evaluation of high-volume hemofiltration in adult burn patients with Septic shock and acute kidney injury (RESCUE) trial. Clinicaltrials.gov Registration Number: NCT01213914. All adult patients aged 18 or older, admitted with severe burns placed on RRT for acute indications during their hospitalization but not randomized into the RESCUE trial, were included. Patients already on dialysis for end-stage renal disease (ESRD) at the time of admission were excluded. As the RESCUE trial was already enrolling subjects when this protocol was written, patients placed on RRT before approval of this protocol were identified retrospectively. On approval of the study at each study site, patients were prospectively enrolled after obtaining informed consent from either the patient or the legal authorized representative when patients were not able to give their own consent.

Demographic data, injury characteristics, physiological and laboratory data around the period of RRT initiation, and various outcomes data were captured and entered into a web-based electronic data management portal (Velos, Inc., Fremont, CA). Specifically, the following information related to RRT was recorded: AKI stage at the time of RRT initiation, as defined by the KDIGO criteria; mode of RRT; prescribed and delivered dose of therapy; the type of prescribing provider (nephrologist vs non-nephrologist); and method of regional anticoagulation used. Additionally, need for RRT on hospital discharge among survivors was captured. Among those who survived to be discharged on RRT, a follow-up audit was performed to determine whether survivors remained on RRT at 6-months post-hospitalization.

Baseline, physiological, and laboratory data were summarized using basic descriptive statistics. Continuous variables were reported in means with standard deviations. Categorical variables were reported in proportions and analyzed using chi-squared tests or Fisher’s exact test as appropriate. Significance for results was established when P-values were less than .05. All statistical analyses were performed using SPSS v22.0.

RESULTS

Across eight participating burn centers, 171 subjects were enrolled during a 4-year period, 143 retrospectively and 28 prospectively. One retrospectively identified patient was excluded due to incomplete data, leaving us with a final sample size of 170 subjects for the study. Figure 1 depicts the CONSORT diagram that illustrates breakdown of those enrolled into the randomized controlled trial vs the observational study. Patient demographics are depicted in Table 1. On average (±SD), patients were initiated on RRT 12 ± 17 days after admission. At the time of RRT initiation, 54% had stage 3 AKI, 18% stage 2, and 22% with stage 1 via KDIGO criteria. Ten patients (6%) did not meet criteria for AKI. The vast majority of patients (94%) also required mechanical ventilation with 61% diagnosed with acute respiratory distress syndrome (ARDS) on initiation of RRT. Patients had an average positive fluid balance of 6.5 ± 6.6 l in the 24 hours before RRT initiation. Additionally, almost half the patients (46%) were in shock, requiring vasopressor support. Other clinical diagnoses and various laboratory data at the time of RRT initiation are presented in Table 2.

RRT prescription characteristics for those enrolled are characterized in Table 3. All but three patients (2%) received continuous RRT (CRRT). Continuous venovenous hemofiltration (CVVH) was the preferred mode of therapy in this population. Prescribing physicians, most of whom were CRRT-credentialed burn surgeons, prescribed a relatively high average blood flow with a relatively high dose of therapy among patients whom data were available (n = 99). On average, patients remained on RRT for 13 ± 24 days and most were regionally anticoagulated on either heparin or citrate.
Aggregate and cohort outcomes data are presented in Table 4. Overall, in hospital, mortality was 50%. No significant differences in mortality were noted when comparing modes of RRT, AKI stage at time of initiation, prescribing physician, or anticoagulation strategy. Among survivors, 21% required RRT on discharge from the hospital while 9% continued to require RRT 6 months after discharge.

**DISCUSSION**

To date, this is the largest multicenter observational study assessing the characteristics of RRT and resultant outcomes as applied to the critically ill burn population. A number of key findings deserve to be emphasized from our study. First, the preferred RRT mode in this population was CVVH, with more than half receiving this mode of therapy. Although there are obvious theoretical benefits of leveraging convec-tive clearance for a better metabolic control, previous studies have not demonstrated a difference in clinical outcomes.10,11 Additionally, there is no convincing evidence to date that continuous therapies are superior to intermittent therapies in terms of biochemical efficacy and mortality rate.12 Still, there is general agreement in the nephrology and critical care community that continuous therapies are better tolerated and thus more desirable and patients who are hemodynamically unstable.9 In this cohort, nearly half the patients were in shock and required vasopressor support. Thus, it reasonably justifies the approach taken in these patients with that vast majority being placed on continuous modalities. Furthermore, we have found previously that CVVH is well tolerated in this population and may even be therapeutic in the form of shock reversal based on a recent randomized controlled trial.8,13

**Table 1.** Baseline demographics (mean ± SD)

| Variable         | (n = 170) |
|------------------|-----------|
| Age              | 51 ± 17   |
| Gender (% male)  | 80%       |
| Height (cm)      | 173 ± 10  |
| Weight (kg)      | 88 ± 26   |
| %TBSA            | 38 ± 26   |
| % FT             | 24 ± 25   |
| Inhalation       | 34%       |
| ISS              | 27 ± 21   |
| APACHE II        | 26 ± 9    |

TBSA, total body surface area; FT, full thickness; ISS, injury severity score; APACHE, acute physiology and chronic health evaluation; RRT, renal replacement therapy.

**Table 2.** Characteristics on the day of RRT initiation (mean ± SD)

| Variable                          | (n = 170) |
|-----------------------------------|-----------|
| Day of RRT initiation             | 12 ± 17   |
| KDIGO AKI stage                   |           |
| Stage 1                           | 22%       |
| Stage 2                           | 18%       |
| Stage 3                           | 54%       |
| No AKI                            | 6%        |
| Mechanical ventilation            | 94%       |
| ARDS                              | 61%       |
| Pneumonia                         | 36%       |
| Bacteremia                        | 22%       |
| Urinary tract infection           | 10%       |
| Wound infection                   | 15%       |
| Vasoppressors                     | 46%       |
| Preceding 24-hr fluid balance (l) | 6.5 ± 6.6 |
| Sodium (mmol/l)                   | 142 ± 6   |
| Potassium (mmol/l)                | 4.5 ± 0.8 |
| Chloride (mmol/l)                 | 107 ± 7   |
| HCO3 (mEq/l)                      | 22 ± 6    |
| BUN (mg/dl)                       | 52 ± 34   |
| Magnesium (mg/dl)                 | 2.2 ± 0.7 |
| Phosphate (mg/dl)                 | 4.4 ± 1.9 |
| Ionized calcium (mmol/l)          | 1.0 ± 0.3 |
| Arterial pH                       | 7.32 ± 0.11 |
| Arterial PaCO2 (mmHg)             | 44 ± 12   |
| Arterial PaO2 (mmHg)              | 141 ± 79  |
| FiO2                              | 60 ± 20   |
| PFR                               | 265 ± 157 |
| Heart rate                        | 105 ± 22  |
| Systolic (mmHg)                   | 120 ± 22  |
| Mean arterial pressure (mmHg)     | 78 ± 15   |

RRT, renal replacement therapy; KDIGO, Kidney Disease: Improving Global Outcomes; AKI, acute kidney injury; ARDS, acute respiratory distress syndrome; BUN, blood urea nitrogen; PFR, partial pressure of oxygen to fraction of inspired oxygen ratio; MAP, mean arterial pressure.

**Table 3.** Renal replacement therapy characteristics

| Variable                          | (n = 170) |
|-----------------------------------|-----------|
| Initial mode                      |           |
| CVVH                              | 54%       |
| CVVHDF                            | 30%       |
| CVVHD                             | 14%       |
| IHD/SLED                          | 2%        |
| Prescribing physician             |           |
| Burn Surgeon                      | 67%       |
| Nephrologist                      | 21%       |
| Nonsurgical intensivist           | 10%       |
| Other                             | 2%        |
| Blood flow (ml/min)               | 240 ± 84  |
| Prescribed dose (ml/kg/hr)        | 42 ± 16 (n = 99) |
| Delivered dose (ml/kg/hr)         | 37 ± 19 (n = 77) |
| Day of RRT initiation             | 12 ± 17   |
| Treatment duration                | 13 ± 24   |
| Anticoagulation                   |           |
| Heparin                           | 26%       |
| Citrate                           | 36%       |
| None                              | 35%       |
| Other                             | 3%        |
| First 24-hr fluid balance (L)     | 3.1 ± 8.2 |
| In-hospital mortality             | 50%       |
| RRT at time of discharge          | 21%       |
| RRT after 6 months                | 9%        |

Abbreviations: CVVH, continuous veno-venous hemofiltration; CVVHDF, continuous veno-venous hemodiafiltration; CVVHD, continuous veno-venous hemodialysis; IHD, intermittent hemodialysis; SLED, sustained low efficiency dialysis.
Table 4. Outcomes

| Variable                        | (n = 170) | P |
|---------------------------------|-----------|---|
| In-hospital mortality           | 50%       |   |
| Mortality based on cohort       |           |   |
| Mode of RRT                     |           |   |
| CVVH, (n = 92)                  | 44%       | 0.15 |
| CVVHDF, (n = 24)                | 70%       |   |
| CVVHDF, (n = 51)                | 50%       |   |
| IHD/SLED, (n = 3)               | 67%       |   |
| AKI subgroup                    |           |   |
| No AKI, (n = 10)                | 60%       | 0.28 |
| AKI Stage 1, (n = 37)           | 62%       |   |
| AKI Stage 2, (n = 30)           | 47%       |   |
| AKI Stage 3, (n = 92)           | 45%       |   |
| Prescribing physician           |           |   |
| Burn surgeon, (n = 114)         | 48%       | 0.79 |
| Nephrologist, (n = 34)          | 50%       |   |
| Non-surgeon intensivist, (n = 18)| 61%   |   |
| Regional anticoagulation        |           |   |
| Heparin, (n = 44)               | 44%       | 0.50 |
| Citrate, (n = 62)               | 52%       |   |
| None, (n = 60)                  | 53%       |   |
| RRT at time of discharge        | 21%       |   |
| RRT after 6 mo                  | 9%        |   |

RRT, renal replacement therapy; CVVH, continuous veno-venous hemofiltration; CVVHDF, continuous veno-venous hemodiafiltration; CVVHDF, continuous veno-venous hemodialysis; IHD, intermittent hemodialysis; SLED, sustained low efficiency dialysis; AKI, acute kidney injury.

The second important finding is that the average dose of therapy, both prescribed and delivered, was relatively high compared with what is typically recommended based on high quality evidence.14,15 Although this information was not reliably available in all patients, it provides important insight into current practice patterns within the burn critical care community. The profound and sustained hypercatabolic states observed in the severely burned have been well documented.16 This predisposes these patients to profound metabolic disturbances that may benefit from a relatively higher dose of therapy. Interestingly, Yoon et al recently reported an overall mortality of 81% in this population treating primarily with continuous veno-venous hemodiafiltration (CVVHDF) at prescribed doses around 30 ml/kg/hour.

The third point of emphasis centers on the timing of RRT initiation. Based on the breakdown of AKI stage at the time of RRT initiation, there is suggestion that most of these patients were put on relatively early. In the management of burn patients with severe AKI, a traditional approach of waiting for classic triggers for initiation of RRT (such as acidosis, severe electrolyte abnormalities, intractable fluid overload, and uremic complications) may result in an unacceptably high mortality. An aggressive approach of initiating RRT with early AKI combined with metabolic derangements led us to an absolute reduction in mortality by 30% when compared with historical controls, most of whom never met classic criteria for renal replacement and thus were not offered RRT.8 One recent single center randomized control trial validated a similarly aggressive approach.7 Unfortunately, another multicenter study did not show a difference in outcome.17 A recent meta-analysis suggests no added benefit of early initiation of RRT.18

The fourth intriguing finding for our study was that the mortality rate observed is the lowest ever reported in this population. Overall, hospital mortality among thousands of critically ill patients who develop AKI in a multinational study was 60%.19 Mortality as high as 80% has been reported among those requiring RRT.10 Hence, this relatively low mortality rate of 50% in the severely burned is quite remarkable. It could be argued that some of these patients may have been placed on RRT when they would have otherwise recovered their renal function without it. However, it could be that the combination of early initiation along with a relatively high intensity of therapy that was individualized may explain this low mortality. In a recent meta-analysis, the only subgroup that seemed to benefit from high intensity RRT was patients with post-surgical AKI.20

Finally, the majority of survivors experienced renal recovery as evidenced by being off of RRT at discharge and at a minimum 6-month follow-up post-discharge. In fact, a 90% recovery rate amongst survivors is similar to what has been reported in the past from other studies.21,22

This study is not without some limitations. The vast majority of data collection occurred retrospectively, although some of these patients were identified prospectively. Additionally, this observational study ran concurrent with a prospective interventional trial.13 Thus, those that met inclusion and exclusion criteria for that study were not included into this one. The overall in-hospital mortality in that interventional trial (n = 37) was 62%. The relatively low mortality of 50% must be interpreted in that context. Finally, there is inherent bias that could be present due to the fact that all participating centers had an existing RRT program with a preference towards continuous modes. This bias must be taken into consideration when interpreting our findings.

CONCLUSION

This is the largest multicenter cohort of critically ill burn patients who underwent RRT reported to date. Most patients who survived to discharge eventually recovered renal function. Timely initiation of RRT with an individualized preference towards continuous modes at relatively higher than recommended doses has become standard practice in critically ill burns with AKI and is associated with a historically low mortality.

ACKNOWLEDGEMENTS

We are indebted to Dr. Daniel M. Caruso for his vision as being among the first in the burn community to embrace this technique in the care of the critically ill over 30 years ago. As such we dedicate this manuscript in his memory. We would also like to specifically acknowledge tremendous work done by our research nurses and coordinators to facilitate the conduct of this of this trial: Erica A. Pamplin, Cathy A. Rauschendorfer, Sonya Charo-Griego, Victoria D. Hatem, Javance R. Tercero, and Linda S. Welker, United States Army Institute of Surgical Research; Thanh Tran and Kristina R. Bolling, MPH, University of South Florida Tampa General Hospital; Peggy
REFERENCES

1. Brusselaer N, Monreal S, Colpaert K, et al. Outcome of acute kidney injury in severe burns: a systematic review and meta-analysis. Intensive Care Med 2010;36:915–25.

2. Leblanc M, Thibeault Y, Quérin S. Continuous haemofiltration and haemo-dialfiltration for acute renal failure in severely burned patients. Burns 1997;23:160–68.

3. Yoon J, Kim Y, Kym D, et al. Subgroup analysis of continuous renal replacement therapy in severely burned patients. PLoS One 2017;12:e0189057.

4. Nash DM, Przech S, Wald R, O’Reilly D. Systematic review and meta-analysis of renal replacement therapy modalities for acute kidney injury in the intensive care unit. J Crit Care 2017;41:138–44.

5. Irriguable TMT, Riera JS, Lopez de Brinas EP, et al. Current practice in continuous renal replacement therapy: an epidemiological multicenter study. Med Intensiva 2017;41:216–26.

6. Gaudry S, Hajage D, Schortgen F, et al.; AKIKI Study Group. Initiation strategies for renal replacement therapy in the intensive care unit. N Engl J Med 2016;375:122–33.

7. Zarbock A, Kellum JA, Schmidt C, et al. Effect of early vs delayed initiation of renal replacement therapy on mortality in critically ill patients with acute kidney injury: the ELAIN randomized clinical trial. JAMA 2016;315:2190–199.

8. Chung KK, Lundy JR, Matson JR, et al. Continuous venovenous hemofiltration in severely burned patients with acute kidney injury: a cohort study. Crit Care 2009;13:R62.

9. Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl 2012;2:1–138.

10. Tolwani A. Continuous renal-replacement therapy for acute kidney injury. N Engl J Med 2012;367:2505–14.

11. Friedrich JO, Wald R, Bagshaw SM, Burns KE, Adhikari NK. Hemofiltration compared to hemodialysis for acute kidney injury: systematic review and meta-analysis. Crit Care 2012;16:R146.

12. Zhang L, Yang J, Eastwood GM, Zhu G, Tanaka A, Bellomo R. Extended daily dialysis versus continuous renal replacement therapy for acute kidney injury: a meta-analysis. Am J Kidney Dis. 2015;66:322–30.

13. Chung KK, Coates EC, Smith DJ Jr, et al.; Randomized controlled Evaluation of high-volume hemofiltration in adult burn patients with Septic shock and acute kidney injury (RESCUE) Investigators. High-volume hemofiltration in adult burn patients with septic shock and acute kidney injury: a multicenter randomized controlled trial. Crit Care 2017;21:289.

14. Palevsky PM, Zhang JH, O’Connor TZ, et al.; VA/NIH Acute Renal Failure Trial Network. Intensity of renal support in critically ill patients with acute kidney injury: a randomized trial. N Engl J Med 2009;361:1627–38.

15. Jeschke MG, Chinkes DL, Finnerty CC, et al. Pathophysiologic response to severe burn injury. Ann Surg 2008;248:387–401.

16. Gaudry S, Hajage D, Schortgen F, et al.; AKIKI Study Group. Initiation strategies for renal-replacement therapy in the intensive care unit. N Engl J Med 2016;375:122–33.

17. Chandra GC and Das RR. Early versus late initiation of renal replacement therapy in patients with acute kidney injury: a systematic review & meta-analysis. Crit Care 2010;14:21.

18. Chandra GC and Das RR. Early versus late initiation of renal replacement therapy in critically ill patients: a meta-analysis. Crit Care Med 2010;38:122–33.

19. Uchino S, Kellum I, Bellomo R, et al.; Beginning and Ending Supportive Therapy for the Kidney (BEST Kidney) Investigators. Acute renal failure in critically ill patients: a multicenter, multinational study. JAMA 2005;294:813–18.

20. Fayad AL, Buamscha DG, Ciappi A. Intensity of continuous renal replacement therapy for acute kidney injury. Cochrane Database Syst Rev 2014;10:CD010613.

21. Gallagher M, Cass A, Bellomo R, et al.; POST-RENAL Study Investigators and the ANZICS Clinical Trials Group. Long-term survival and dialysis dependency following acute kidney injury in intensive care: extended follow-up of a randomized controlled trial. PLoS Med 2014;11:e1001601.

22. Palevsky PM, O’Connor TZ, Chertow GM, Crowley ST, Zhang JH, Kellum JA; US Department of Veterans Affairs/National Institutes of Health Acute Renal Failure Trial Network. Intensity of renal replacement therapy in acute kidney injury: perspective from within the Acute Renal Failure Trial Network Study. Crit Care 2009;13:310.